Table 2.
Baseline characteristics by study drug and timing of use among pregnancies identified from the British Columbia healthcare utilization databases between 1997–2006 in which women had Disease-Modifying Antirheumatic Drug (DMARD), corticosteroid or nonsteroidal anti-inflammatory drugs (NSAID) use, but no diagnostic codes for organ transplant, malaria or cancer. N (percent) unless otherwise noted.
| Baseline Characteristics | DMARD Use, N=1,220 | Corticosteroid Use, N=7,282 | NSAID Use, N=36,284 | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Past N=918 | Contin. N=183 | First-time N=119 | Past N=5,940 | Contin. N=456 | First-time N=886 | Past N=31,556 | Contin. N=2,036 | First-time N=2,692 | |
| Delivery Year | |||||||||
| 1997–2000 | 422 (45.9) | 44 (24.0) | 46 (38.7) | 2,344 (39.5) | 185 (40.6) | 341 (38.5) | 12,648 (40.1) | 800 (39.3) | 1,085 (40.3) |
| 2001–2003 | 293 (32.0) | 76 (41.5) | 39 (32.8) | 2,136 (36.0) | 153 (33.6) | 313 (35.3) | 11,783 (37.3) | 771 (37.9) | 943 (35.0) |
| 2004–2006 | 203 (22.1) | 63 (34.4) | 34 (28.6) | 1,460 (24.6) | 118 (25.9) | 232 (26.2) | 7,125 (22.6) | 465 (22.8) | 664 (24.7) |
| Age, Median (IQ Range) | 30 (6) | 33 (7) | 31 (8) | 30 (7) | 32 (8) | 30 (8) | 30 (7) | 30 (8) | 30 (8) |
| Primiparity | 725 (79.0) | 125 (68.3) | 93 (78.2) | 4,385 (73.8) | 329 (72.2) | 632 (71.3) | 23,860 (75.6) | 1,484 (72.9) | 1,940 (72.1) |
| Multifetal Gestation | 10 (1.1) | 5 (2.7) | 0 (0) | 81 (1.4) | 21 (4.6) | 21 (2.4) | 333 (1.1) | 26 (1.3) | 27 (1.0) |
| Hypertension (Diagnosis or Antihypertensive) | 33 (3.6) | 17 (9.3) | 6 (5.0) | 249 (4.2) | 33 (7.2) | 36 (4.1) | 1294 (4.1) | 157 (7.7) | 99 (3.7) |
| Diabetes Mellitus | 3 (0.3) | 2 (1.1) | 0 (0) | 47 (0.8) | 9 (2.0) | 9 (1.0) | 286 (0.9) | 26 (1.3) | 32 (1.2) |
| Asthma | 31 (3.4) | 10 (5.5) | 4 (3.4) | 979 (16.5) | 107 (23.5) | 102 (11.5) | 1,598 (5.1) | 140 (6.9) | 131 (4.9) |
| Renal Disease | 2 (0.22) | 6 (3.3) | 1 (0.8) | 19 (0.3) | 10 (2.2) | 6 (0.7) | 113 (0.4) | 16 (0.8) | 8 (0.3) |
| RA/Psoriasis | 101 (11.0) | 33 (18.0) | 4 (3.4) | 76 (1.3) | 48 (10.5) | 6 (0.7) | 208 (0.7) | 42 (2.1) | 8 (0.3) |
| SLE | 26 (2.8) | 28 (15.3) | 3 (2.5) | 24 (0.4) | 23 (5.0) | 5 (0.6) | 57 (0.2) | 9 (0.4) | 0 (0) |
| IBD | 47 (5.1) | 34 (18.6) | 2 (1.7) | 126 (2.1) | 33 (7.2) | 10 (1.1) | 77 (0.2) | 2 (0.1) | 5 (0.2) |
| MS | 0 (0) | 0 (0) | 0 (0) | 24 (0.4) | 2 (0.4) | 0 (0) | 28 (0.1) | 3 (0.2) | 4 (0.2) |
| Osteoarthritis | 68 (7.4) | 36 (19.7) | 4 (3.4) | 127 (2.1) | 34 (7.5) | 13 (1.5) | 812 (2.6) | 106 (5.2) | 22 (0.8) |
| Unspecified Joint Disorders | 51 (5.6) | 16 (8.7) | 3 (2.5) | 278 (4.7) | 24 (5.3) | 42 (4.7) | 1,640 (5.2) | 136 (6.7) | 82 (3.1) |
| Back/Neck Disorders | 147 (16.0) | 35 (19.1) | 18 (15.1) | 1,032 (17.4) | 97 (21.3) | 146 (16.5) | 8,842 (28.0) | 709 (34.8) | 430 (16.0) |
| Soft Tissue Disorders | 116 (12.6) | 22 (12.0) | 12 (10.1) | 903 (15.2) | 65 (14.3) | 124 (14.0) | 6,687 (21.2) | 524 (25.7) | 300 (11.1) |
| Sprain/Strain | 164 (17.9) | 31 (16.9) | 24 (20.2) | 1,206 (20.3) | 88 (19.3) | 163 (18.4) | 10,195 (32.3) | 758 (37.2) | 463 (17.2) |
| Headache/Migraine | 124 (13.5) | 20 (10.9) | 16 (13.5) | 1,098 (18.5) | 71 (15.6) | 143 (16.1) | 6,530 (20.7) | 627 (30.8) | 401 (14.9) |
| PMT/Menstruation Disorders | 340 (37.0) | 48 (26.2) | 29 (24.4) | 2,171 (36.6) | 155 (34.0) | 304 (34.3) | 13,249 (42.0) | 950 (46.7) | 1,000 (37.2) |
| ≥2 Rheumatology Visits | 93 (10.1) | 76 (41.5) | 6 (5.0) | 84 (1.4) | 71 (15.6) | 10 (1.1) | 249 (0.8) | 51 (2.5) | 8 (0.3) |
| Joint Radiograph | 79 (8.6) | 31 (16.9) | 9 (7.6) | 577 (9.7) | 57 (12.5) | 84 (9.5) | 4,499 (14.3) | 341 (16.8) | 178 (6.6) |
| Platelet Count | 67 (7.3) | 55 (30.1) | 4 (3.4) | 138 (2.3) | 54 (11.8) | 19 (2.1) | 491 (1.6) | 54 (2.7) | 33 (1.2) |
| Number of Physician visits, Median (IQ Range) | 14.5 (13) | 19 (19) | 12 (15) | 15 (15) | 21 (18) | 14 (14) | 16 (15) | 22 (20) | 14 (14) |
| Number of Non- Study Drugs, Median (IQ Range) | 3 (3) | 3 (4) | 2 (3) | 4 (4) | 5 (5) | 3 (4) | 3 (3) | 5 (6) | 2 (3) |
| Total Days Supply of Baseline DMARDs, Median (IQ Range) | 56 (80) | 270 (210) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Total Days Supply of Baseline Corticosteroids | |||||||||
| 0 | 782 (85.2) | 104 (56.8) | 111 (93.3) | 0 (0) | 0 (0) | 0 (0) | 29,750 (94.3) | 1,889 (92.8) | 2,612 (97.0) |
| 1–6 | 9 (0.98) | 6 (3.3) | 2 (1.7) | 3,346 (56.3) | 70 (15.4) | 0 (0) | 1,069 (3.4) | 68 (3.3) | 40 (1.5) |
| 7–89 | 63 (6.9) | 18 (9.8) | 2 (1.7) | 2,381 (40.1) | 212 (46.5) | 0 (0) | 645 (2.0) | 60 (3.0) | 32 (1.2) |
| ≥90 | 64 (7.0) | 55 (30.1) | 4 (3.4) | 213 (3.6) | 174 (38.2) | 0 (0) | 92 (0.3) | 19 (0.9) | 8 (0.3) |
| Total Days Supply of Baseline NSAIDs | |||||||||
| 0 | 666 (72.6) | 125 (68.3) | 99 (83.2) | 4,104 (69.1) | 339 (74.3) | 710 (80.1) | 0 (0) | 0 (0) | 0 (0) |
| 1–6 | 18 (2.0) | 2 (1.1) | 2 (1.7) | 425 (7.2) | 10 (2.2) | 25 (2.8) | 5,202 (16.5) | 178 (8.7) | 0 (0) |
| 7–89 | 178 (19.4) | 22 (12.0) | 15 (12.6) | 1329 (22.4) | 73 (16.0) | 140 (15.8) | 25,522 (80.9) | 1,557 (76.5) | 0 (0) |
| ≥90 | 56 (6.1) | 34 (18.6) | 3 (2.5) | 82 (1.4) | 34 (7.5) | 11 (1.2) | 832 (2.6) | 301 (14.8) | 0 (0) |
Abbreviations: Cont., Continuous; IBD, Inflammatory Bowel Disease; IQ, interquartile; MS, multiple sclerosis; NSAID, nonsteroidal anti-inflammatory; PMT, premenstrual tension syndrome; RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic; SLE, systemic lupus erythematosus.